ERCC5

DNA excision repair protein ERCC-5

19,481 patent compounds predicted against ERCC5, 13,756 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL292473	0.46	8/20
SCHEMBL440631	0.65	4/20
SCHEMBL441329	0.65	4/20
Silver (SCHEMBL527868)	0.65	4/20
SCHEMBL383767	0.46	4/20
SCHEMBL115267	0.45	4/20
SCHEMBL636225	0.59	3/20
SCHEMBL70968	0.58	3/20
SCHEMBL419161	0.52	3/20
SCHEMBL271455	0.50	3/20
Phenylpyruvate (SCHEMBL616906)	0.50	3/20
SCHEMBL92196	0.49	3/20
SCHEMBL419159	0.48	3/20
SCHEMBL419160	0.47	3/20
Dibenzoylmethane (SCHEMBL39582)	0.73	2/20
Dibenzoylmethane (SCHEMBL531257)	0.70	2/20
SCHEMBL599285	0.68	2/20
SCHEMBL269381	0.68	2/20
SCHEMBL98540	0.67	2/20
SCHEMBL441330	0.64	2/20

Germline variants in ERCC5 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full ERCC5 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to ERCC5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer	PHASE3	COMPLETED
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients	PHASE3	COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer	PHASE2	COMPLETED
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy	PHASE2	COMPLETED
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer	PHASE2	WITHDRAWN
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer	PHASE2	UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)	PHASE2	COMPLETED
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations	PHASE2	RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Olaparib in People With Malignant Mesothelioma	PHASE2	COMPLETED
Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer	PHASE2	WITHDRAWN
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	PHASE2	COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.	nan	UNKNOWN
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Family Study of Melanoma in Italy	nan	COMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ERCC5 binder may also engage these)

Protein	Name	Similarity
P35689	—	0.996	P35689 →
P14629	—	0.996	P14629 →
Q9R207	—	0.986	Q9R207 →
Q7TN31	—	0.986	Q7TN31 →
Q8K2L8	—	0.985	Q8K2L8 →
Q501R9	—	0.983	Q501R9 →
Q5M954	—	0.983	Q5M954 →
O60934	—	0.983	O60934 →
Q76CY8	—	0.982	Q76CY8 →
Q9JIL9	—	0.982	Q9JIL9 →
Q5QJC2	—	0.981	Q5QJC2 →
Q8IW35	—	0.981	Q8IW35 →
Q6P7W5	—	0.981	Q6P7W5 →
TOR1AIP1	Torsin-1A-interacting protein 1	0.981	landscape →
Q69Z66	—	0.981	Q69Z66 →
Q62187	—	0.981	Q62187 →
Q53F19	—	0.981	Q53F19 →
Q8WYQ5	—	0.980	Q8WYQ5 →
Q5R6Z9	—	0.980	Q5R6Z9 →
Q8BMI4	—	0.980	Q8BMI4 →
Q5XIX3	—	0.980	Q5XIX3 →
Q99549	—	0.980	Q99549 →
Q5RCV3	—	0.980	Q5RCV3 →
Q9XSC3	—	0.980	Q9XSC3 →
F6RIX4	—	0.980	F6RIX4 →
Q6P2K3	—	0.979	Q6P2K3 →
Q9EQM6	—	0.979	Q9EQM6 →
Q9QXK2	—	0.979	Q9QXK2 →
Q6NVE8	—	0.979	Q6NVE8 →
Q17RS7	—	0.979	Q17RS7 →